Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis

Delmas, G.; Park, S.; Chen, Z.W.; Tan, F.; Kashiwazaki, R.; Zarif, L.; Perlin, D.S.

Antimicrobial Agents and ChemoTherapy 46(8): 2704-2707

2002


ISSN/ISBN: 0066-4804
PMID: 12121962
DOI: 10.1128/aac.46.8.2704-2707.2002
Accession: 003747652

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 0-6 h
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Cochleates containing amphotericin B (CAMB) were administered orally at doses ranging from 0 to 40 mg/kg of body weight/day for 14 days in a mouse model of systemic aspergillosis. The administration of oral doses of CAMB (20 and 40 mg/kg/day) resulted in a survival rate of 70% and a reduction in colony counts of >2 logs in lungs, livers, and kidneys. Orally administered CAMB shows promise for the treatment of aspergillosis.